7 completed. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 7 |
Follow Overactive Bladder (OAB): new trials by email Literature Review of Overactive Bladder (OAB) trials Research Report on Overactive Bladder (OAB)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder 17β-estradiol 10 mcg - Overactive Bladder (OAB), Menopause | Phase 4 | Completed | Mahidol University | 30 | 2025-06-27 | 2026-02-09 |
| A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder mirabegron - Urge Incontinence, Overactive Bladder (OAB) | Phase 4 | Completed | Astellas Pharma China, Inc. | 249 | 2021-01-06 | 2024-11-15 |
| Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. Mirabegron tablet, Solifenacin tablet, Propiverine tablet - Overactive Bladder (OAB) | Phase 4 | Completed | Astellas Pharma Inc | 649 | 2014-10-28 | 2024-10-31 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) Mirabegron, Placebo - Overactive Bladder (OAB) | Phase 4 | Completed | Astellas Pharma Global Development, Inc. | 888 | 2014-10-07 | 2024-11-22 |
| A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) Mirabegron, Tolterodine ER - Overactive Bladder (OAB) | Phase 4 | Completed | Astellas Pharma Global Development, Inc. | 376 | 2014-07-24 | 2020-02-26 |
| Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder Darifenacin - Overactive Bladder (OAB) | Phase 4 | Completed | Novartis | 500 | 2006-06-01 | 2008-01-15 |
| Detrol LA In Men With Overactive Bladder. Detrol LA - Overactive Bladder (OAB) | Phase 4 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 600 | 2006-01-01 | 2021-01-27 |
Urinary Bladder, Overactive (7) · Urinary Incontinence (1) · Urinary Incontinence, Urge (1)
Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Lower Urinary Tract Symptoms (7) · Male Urogenital Diseases (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Urinary Bladder Diseases (7) · Urogenital Diseases (7) · Urologic Diseases (7) · Urological Manifestations (7) · Urination Disorders (2) · Urinary Incontinence (1)
mirabegron (4) · Tolterodine Tartrate (3) · Estradiol (1) · Solifenacin Succinate (1) · darifenacin (1) · imidafenacin (1) · propiverine (1)
Astellas Pharma Global Development, Inc. (2) · Astellas Pharma China, Inc. (1) · Astellas Pharma Inc (1) · Mahidol University (1) · Novartis (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1)
United States (4) · Canada (3) · China (1) · Denmark (1) · Germany (1) · Italy (1) · Japan (1) · Mexico (1) · Norway (1) · Slovakia (1) · South Africa (1) · South Korea (1) · Spain (1) · Sweden (1) · Taiwan (1)
PMID 18811599, PMID 19070418, PMID 20860020, PMID 32183741, PMID 32725584